CN107614015A - 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 - Google Patents

治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 Download PDF

Info

Publication number
CN107614015A
CN107614015A CN201680031816.8A CN201680031816A CN107614015A CN 107614015 A CN107614015 A CN 107614015A CN 201680031816 A CN201680031816 A CN 201680031816A CN 107614015 A CN107614015 A CN 107614015A
Authority
CN
China
Prior art keywords
ser
val
leu
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680031816.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·E·瓜尔迪诺
M·萨曼特
A·斯特拉萨克
M·斯密特
M·帕特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN107614015A publication Critical patent/CN107614015A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680031816.8A 2015-05-30 2016-05-27 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 Pending CN107614015A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168809P 2015-05-30 2015-05-30
US62/168,809 2015-05-30
PCT/US2016/034835 WO2016196373A2 (en) 2015-05-30 2016-05-27 Methods of treating her2-positive metastatic breast cancer

Publications (1)

Publication Number Publication Date
CN107614015A true CN107614015A (zh) 2018-01-19

Family

ID=56134616

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680031816.8A Pending CN107614015A (zh) 2015-05-30 2016-05-27 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法

Country Status (15)

Country Link
US (2) US11406715B2 (https=)
EP (1) EP3302551B1 (https=)
JP (4) JP6822980B2 (https=)
CN (1) CN107614015A (https=)
DK (1) DK3302551T3 (https=)
ES (1) ES2984592T3 (https=)
FI (1) FI3302551T3 (https=)
HR (1) HRP20241134T1 (https=)
HU (1) HUE068105T2 (https=)
LT (1) LT3302551T (https=)
PL (1) PL3302551T3 (https=)
PT (1) PT3302551T (https=)
RS (1) RS65871B1 (https=)
SI (1) SI3302551T1 (https=)
WO (1) WO2016196373A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113543805A (zh) * 2018-10-21 2021-10-22 Slsg有限责任公司 联合免疫疗法用于治疗三阴性乳腺癌

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210330801A1 (en) * 2017-03-02 2021-10-28 Cadila Healthcare Limited Novel protein drug conjugate formulation
US20200114018A1 (en) * 2018-10-15 2020-04-16 Genentech, Inc. Methods of treating residual breast cancer with trastuzumab emtansine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP0950067B1 (en) 1996-11-27 2007-08-29 Genentech, Inc. Affinity purification of polypeptide on protein a matrix
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JP2002507404A (ja) 1998-03-27 2002-03-12 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド−抗ＨＥＲ−２抗体相乗作用
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
JP5623681B2 (ja) 1999-05-14 2014-11-12 ジェネンテック， インコーポレイテッド 抗−ＥｒｂＢ２抗体による治療
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
IL147017A0 (en) 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
KR20130056201A (ko) 2000-05-19 2013-05-29 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
SI1543038T2 (sl) 2002-09-11 2020-12-31 Genentech, Inc. Čiščenje proteinov
JP2006516117A (ja) 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
EP1648940B1 (en) 2003-07-28 2016-04-27 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
US7004206B2 (en) 2004-01-29 2006-02-28 Viken James P Automatic fluid exchanger
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523073A (ja) 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
MY157955A (en) 2005-07-06 2016-08-30 Hoffmann La Roche Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
JP2009539836A (ja) 2006-06-05 2009-11-19 ジェネンテック・インコーポレーテッド ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長
DK2056874T3 (da) 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
MX2009012838A (es) 2007-06-06 2009-12-11 Hoffmann La Roche Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CN101889025B (zh) 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP2260056A1 (en) 2008-03-06 2010-12-15 Genentech, Inc. Combination therapy with c-met and her antagonists
NZ602675A (en) 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
BR112013014316A2 (pt) 2010-12-09 2016-09-27 Genentech Inc tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MANFRED WELSLAU等: "Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer", 《CANCER》 *
SANDRA M SWAIN等: "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study", 《LANCET ONCOL》 *
SARA A. HURVITZ等: "Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer", 《JOURNAL OF CLINICAL ONCOLOGY》 *
SUNIL VERMA等: "Trastuzumab emtansine for HER2-positive advanced breast cancer", 《N ENGL J MED》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113543805A (zh) * 2018-10-21 2021-10-22 Slsg有限责任公司 联合免疫疗法用于治疗三阴性乳腺癌

Also Published As

Publication number Publication date
WO2016196373A3 (en) 2017-02-02
JP2018516920A (ja) 2018-06-28
JP7330217B2 (ja) 2023-08-21
US11406715B2 (en) 2022-08-09
FI3302551T3 (fi) 2024-08-27
US20220354961A1 (en) 2022-11-10
SI3302551T1 (sl) 2024-10-30
ES2984592T3 (es) 2024-10-30
PT3302551T (pt) 2024-08-21
EP3302551B1 (en) 2024-06-26
JP2025157247A (ja) 2025-10-15
JP2023100635A (ja) 2023-07-19
JP2021073203A (ja) 2021-05-13
JP6822980B2 (ja) 2021-01-27
RS65871B1 (sr) 2024-09-30
WO2016196373A2 (en) 2016-12-08
HRP20241134T1 (hr) 2024-11-22
LT3302551T (lt) 2024-09-10
PL3302551T3 (pl) 2024-09-30
HUE068105T2 (hu) 2024-12-28
DK3302551T3 (da) 2024-08-26
EP3302551A2 (en) 2018-04-11
WO2016196373A8 (en) 2017-11-30
US20190030181A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
AU2015249633B2 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
US20200069694A1 (en) Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
TW202038957A (zh) 抗體-藥物結合物與激酶抑制劑之組合
US20220354961A1 (en) Methods of treating her2-positive metastatic breast cancer
KR102697939B1 (ko) 항-her2 항체-약물 접합체 및 bcl-2 억제제를 사용한 병용 요법
HK1249444A1 (en) Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
HK1226957A1 (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
HK40060423B (zh) 抗her2抗体-药物缀合物和bcl-2抑制剂的组合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1249444

Country of ref document: HK